{"id":"W4391933719","doi":"10.1016/j.annonc.2024.02.005","title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"AstraZeneca; AstraZeneca United States","keywords":"Durvalumab; Tremelimumab; Medicine; Sorafenib; Hepatocellular carcinoma; Oncology; Internal medicine; Confidence interval; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003707036,0.0003212588,0.001082861,0.0003502909,0.0003175848,0.0008508271,0.0004619124,0.0003012389,0.0009900711],"category_scores_gemma":[0.00205279,0.000252591,0.0008781416,0.0007771727,0.0002173618,0.0003336806,0.00045737,0.0008681625,0.0002763375],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008605341,"about_ca_system_score_gemma":0.00109982,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003378062,"about_ca_topic_score_gemma":0.007784203,"domain_scores_codex":[0.999083,0.0004548732,0.00005794,0.00008520429,0.0002425558,0.00007639908],"domain_scores_gemma":[0.9978653,0.0004363003,0.0006403897,0.0002850675,0.0003464231,0.0004266697],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.2373817,0.002994982,0.5237703,0.001618119,0.01764423,0.0005256364,0.0007365273,0.00421378,0.01041083,0.0003137608,0.01783962,0.1825506],"study_design_scores_gemma":[0.02713236,0.0119724,0.9336678,0.0001237689,0.007993858,0.0006075083,0.0001181196,0.001052624,0.002162291,0.0001666512,0.01494017,0.00006259888],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9767651,0.007087271,0.0005980982,0.0004953035,0.0000742349,0.0004655445,0.01196197,0.00004057203,0.002511837],"genre_scores_gemma":[0.970706,0.002805467,0.001040429,0.0005211498,0.0001262745,0.0005320954,0.02326261,0.00001677196,0.0009892436],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003707036,"threshold_uncertainty_score":0.01960492,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1856405556875463,"score_gpt":0.3639313170887483,"score_spread":0.178290761401202,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}